{"id":"W4406470071","doi":"10.1186/s13045-024-01657-z","title":"Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; Astellas Pharma; Syndax Pharmaceuticals; Bristol-Myers Squibb; Foghorn Therapeutics; Celgene; Jazz Pharmaceuticals; Leukemia and Lymphoma Society; GlaxoSmithKline; Servier; Daiichi-Sankyo; Pfizer","keywords":"Medicine; Refractory (planetary science); Open label; Myeloid leukemia; Azacitidine; Hematology; Internal medicine; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002810597,0.001127861,0.002185595,0.0004715675,0.0003805027,0.0008775163,0.0007126001,0.0008898829,0.002417269],"category_scores_gemma":[0.0009401382,0.0004822846,0.001513587,0.0004844338,0.0005964069,0.0006852627,0.0003598454,0.002070346,0.0004411587],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006258806,"about_ca_system_score_gemma":0.0008154219,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003973203,"about_ca_topic_score_gemma":0.001524105,"domain_scores_codex":[0.9993049,0.0004103417,0.00004640303,0.00009727368,0.00005997478,0.00008111136],"domain_scores_gemma":[0.9992527,0.0001498929,0.000182565,0.00007580035,0.0000478954,0.0002911011],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8485326,0.02069391,0.008052805,0.001021649,0.003930395,0.0001954037,0.0002190414,0.001182894,0.02621476,0.0001107757,0.001721396,0.08812445],"study_design_scores_gemma":[0.7165599,0.2590931,0.01748778,0.00006153683,0.001458547,0.0003380165,0.00005021254,0.000726198,0.002485797,0.0001197579,0.001589711,0.00002931884],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940932,0.003556397,0.0002557329,0.0002448676,0.00006009811,0.0006829302,0.0003588687,0.00005611684,0.0006918815],"genre_scores_gemma":[0.9943942,0.002087855,0.0007867118,0.0003977015,0.0002170643,0.0006301129,0.0008362496,0.00001841294,0.0006317595],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002810597,"threshold_uncertainty_score":0.01486403,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04688349364955659,"score_gpt":0.3858644542352145,"score_spread":0.338980960585658,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}